• PCVD15- A UK PRIMARY CARE DATABASE (UKPCD)- UK MEDIPLUS IS A READILY AVAILABLE RESEARCH TOOL FOR DETERMINING THE PREVALENCE OF PATIENTS WITH A HISTORY OF OBESITY OR OVERWEIGHT, THEIR TREATMENT, AND ASSOCIATED COMORBIDITIES

    May 1, 1999, 00:00

  • PCVD14- USE OF CONFIDENCE INTERVALS TO ESTIMATE THE COST-EFFECTIVENESS OF ABCIXIMAB

    May 1, 1999, 00:00

  • PAD7- PHARMACOEPIDEMIOLOGY OF INITIAL DISEASE MODIFYING ANTIRHEUMATIC DRUG (DMARD) THERAPY IN A MANAGED CARE ORGANIZATION (MCO)

    May 1, 1999, 00:00

  • TPS1- A COST-EFFECTIVE APPROACH FOR UNIVERSAL COLON CANCER SCREENING IN A MANAGED CARE MODEL

    May 1, 1999, 00:00

  • RM4- OUTCOME ASSESSMENT OF A FALL RISK-REDUCTION PROGRAM- METHODOLOGICAL ISSUES

    May 1, 1999, 00:00

  • RD2- COST-EFFICACY ANALYSIS OF AN INHALED CORTICOSTEROID VERSUS A LEUKOTRIENE RECEPTOR ANTAGONIST

    May 1, 1999, 00:00

  • WTG1- APPLES AND APPLES, APPLES AND ORANGES- THE USE AND ABUSE OF AVERAGE DAILY DOSE IN PHARMACOECONOMIC RESEARCH

    May 1, 1999, 00:00

  • ID4- A COST ANALYSIS OF LEVOFLOXACIN VERSUS CEFTRIAXONE IN ADULT INPATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA

    May 1, 1999, 00:00

  • TPRD2- INCIDENCE OF SMALL-BOWEL OBSTRUCTION AND ADHESIOLYSIS FOLLOWING OPEN COLORECTAL AND GENERAL SURGERY

    May 1, 1999, 00:00

  • PDD5- ONYCHOMYCOSIS AND ITS IMPACT ON SECONDARY INFECTION DEVELOPMENT IN THE DIABETIC POPULATION

    May 1, 1999, 00:00

  • PG14- PRESCRIPTION TO OVER-THE-COUNTER PRODUCTS- HISTAMINE-2-RECEPTOR ANTAGONISTS IN THE USA

    May 1, 1999, 00:00

  • WMM2- ECONOMIC EVALUATION OF PROSPECTIVE MULTINATIONAL CLINICAL TRIALS- A MODELING APPROACH

    May 1, 1999, 00:00

  • WMQ2- A GUIDE FOR SELECTING HEALTH OUTCOMES AND QUALITY OF LIFE MEASURES

    May 1, 1999, 00:00

  • PRD12- DETERMINING THE CLINICAL RELEVANCE OF STATISTICALLY SIGNIFICANT IMPROVEMENTS IN QUALITY OF LIFE

    May 1, 1999, 00:00

  • DM2- MEASURING THE EFFECTIVENESS OF A DIABETES DISEASE MANAGEMENT PROGRAM

    May 1, 1999, 00:00

  • PRD4- COST BENEFIT ANALYSIS OF ASTHMA EDUCATION PROGRAMS

    May 1, 1999, 00:00

  • POR3- EDMONTON QUALITY ASSESSMENT TOOL FOR DRUG UTILIZATION REVIEWS (EQATDUR)- AN INSTRUMENT FOR ASSESSING THE METHODOLOGIC RIGOR OF DRUG UTILIZATION REVIEWS

    May 1, 1999, 00:00

  • POR10- PREDICTING MARKET SHARES FOR NEW PHARMCEUTICAL PRODUCTS USING STATED PREFERENCES

    May 1, 1999, 00:00

  • PAD4- CLINICALLY MEANINGFUL IMPROVEMENT OF HEALTH-RELATED QUALITY OF LIFE (HRQoL) AMONG OSTEOARTHRITIS (OA) PATIENTS

    May 1, 1999, 00:00

  • PPO4- COMMUNITY PHARMACIST ASSESSMENT OF THE MOTIVATIONS FOR PROVIDING PHARMACEUTICAL CARE ACROSS FOUR DOMAINS

    May 1, 1999, 00:00

  • PCD7- INITIAL, MAINTENANCE, AND TERMINAL CARE COSTS OF BREAST CANCER TREATMENT

    May 1, 1999, 00:00

  • PWM9- ECONOMIC EVALUATION IN REAL-LIFE SETTING OF ALPHA-BLOCKERS VERSUS FINASTERIDE VERSUS SERENOA REPENS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

    May 1, 1999, 00:00

  • PNP21- THE ECONOMIC COSTS OF HEROIN ADDICTION

    May 1, 1999, 00:00

  • PPO3- DESIGNING A USER-FRIENDLY OUTCOMES RESEARCH DATABASE FOR THE PRIVATE MEDICAL PRACTITIONER

    May 1, 1999, 00:00

  • PCP8- ASSESSMENT OF SURGICAL ANESTHESIA AND POSTOPERATIVE ANALGESIA USING A PAIN VISUAL ANALOG SCALE

    May 1, 1999, 00:00

  • TPQL4- A TIME SERIES AND PANEL DATA APPROACH TO CROSS-TRANSLATE DESCRIPTIVE HEALTH STATUS TO HEALTH PREFERENCE IN PATIENTS WITH CHRONIC DISEASES

    May 1, 1999, 00:00

  • TPIC2- IMPACT OF ATTENTION DEFICIT AND HYPERACTIVITY DISORDER (ADHD)- A SURVEY OF PRIMARY CAREGIVERS

    May 1, 1999, 00:00

  • WMS4- STATISTICAL ISSUES IN THE DESIGNING AND ANALYZING THE DATA FOR PHARMACOECONOMICS AND OUTCOME STUDIES

    May 1, 1999, 00:00

  • PID7- COST-EFFECTIVE ANALYSIS OF ORAL ONYCHOMYCOSIS THERAPIES USING IDAHO MEDICAID CLAIMS DATA

    May 1, 1999, 00:00

  • PNP3- RACIAL AND GENDER DIFFERENCES IN ACCESS TO A NEW DRUG THERAPY

    May 1, 1999, 00:00

  • TPQL5- A REVIEW AND EVALUATION OF THE EMEA DOCUMENTS WITH REFERENCE TO QUALITY OF LIFE (QOL) ASSESSMENT.

    May 1, 1999, 00:00

  • POR6- EVALUATION OF THE STRUCTURAL VALIDITY OF THE SF-12

    May 1, 1999, 00:00

  • WMM3- MODELING SEQUENTIAL DECISION-MAKING IN PHARMACOECONOMICS

    May 1, 1999, 00:00

  • PCD8- AN ANALYSIS OF RESEARCH AND POLICYRELEVANT CHARACTERISTICS OF QUALITY OF LIFE ASSESSMENTS IN PROSTATE CANCER

    May 1, 1999, 00:00

  • PRD5- THE FIRST PHARMACOECONOMIC STUDY IN ASTHMA- SOME IMPORTANT OBSERVATIONS

    May 1, 1999, 00:00

  • PG11- COSTS AND PRACTICE PATTERNS ASSOCIATED WITH TREATING GASTROESOPHAGEAL REFLUX DISEASE (GERD) IN A MANAGED CARE POPULATION

    May 1, 1999, 00:00

  • Pharmacoeconomic Perspectives in Russia

    May 1, 1999, 00:00

  • TPRD1- PHARMACOECONOMIC ANALYSIS OF WARFARIN VERSUS ENOXAPARIN USED PROPHYLACTICALLY IN HIP SURGERY

    May 1, 1999, 00:00

  • PAD2- OPTIMIZATION OF AN HMOS NSAID PORTFOLIO FOLLOWING THE INTRODUCTION OF CELECOXIB

    May 1, 1999, 00:00

  • PUP2- PHARMACOECONOMIC INFORMATION IN FORMULARY DECISION-MAKING IN THE UNITED STATES

    May 1, 1999, 00:00

  • PPO8- AN EMPIRICAL ANALYSIS ON AMBULATORY CARE UTILIZATION- APPLICATION OF A COUNT DATA MODEL

    May 1, 1999, 00:00

  • ER4- MODELING PHARMACOECONOMIC ANALYSES WITH DISTRIBUTIONS OF RESULTS FROM TRIALS

    May 1, 1999, 00:00

  • PPO2- THE DEVELOPMENT OF A PRACTICAL PROVIDER PROFILING REPORT

    May 1, 1999, 00:00

  • PKU4- LINGUISTIC VALIDATION OF THE KINGS HEALTH QUESTIONNAIRE (KHQ) IN EIGHT LANGUAGES

    May 1, 1999, 00:00

  • TPCP5- THE COST OF DISCONTINUATION OF ANTI-HYPERTENSIVE DRUG THERAPY IN A MEDICAID POPULATION

    May 1, 1999, 00:00

  • PNP14- COST AND UTILIZATION OUTCOMES OF PATIENTS TREATED FOR SCHIZOPHRENIA IN A MEDICAID POPULATION

    May 1, 1999, 00:00

  • PID17- DETERMINATION OF THE COST-EFFECTIVENESS OF A TUBERCULOSIS PREVENTION PROGRAM ALONG THE US/ MEXICO BORDER USING MARKOV PROCESS MODELING WITHIN A PREVENTION EFFECTIVENESS FRAMEWORK

    May 1, 1999, 00:00

  • PKU1- A METHOD FOR COMPARING DISPARATE OUTCOME MEASURES IN OVERACTIVE BLADDER CLINICAL TRIALS

    May 1, 1999, 00:00

  • PCP5- USE OF OPIOID ANALGESICS FOR NONMALIGNANT PAIN CONDITIONS- A CROSS-SECTIONAL CHARACTERIZATION

    May 1, 1999, 00:00

  • TPCP4- DISCRETE CHOICE MODELING ON PATIENT PERCEIVED COMPLIANCE- ANALYSIS OF PATIENTS HEALTH BELIEF PERSPECTIVE

    May 1, 1999, 00:00

  • TPDM7- COST OF ISCHEMIC STROKE TREATMENT BY FUNCTIONAL STATUS- A MODEL COMPARING CITICOLINE TO STANDARD CARE

    May 1, 1999, 00:00

  • PG15- FACTORS INFLUENCING THE DURATION OF GI MEDICATION TREATMENT ASSOCIATED WITH NSAID-INDUCED GASTROPATHY

    May 1, 1999, 00:00

  • TPQL2- SF-36 AS A PREDICTOR OF HEALTH STATES

    May 1, 1999, 00:00

  • PCVD9- LEFT VENTRICULAR SYSTOLIC FUNCTION AND DRUG UTILIZATION AMONG HOSPITALIZED PATIENTS WITH CONGESTIVE HEART FAILURE

    May 1, 1999, 00:00

  • POR8- MINIMAL STANDARDS FOR THE VALIDATION OF QUALITY OF LIFE INSTRUMENTS USED IN CLINICAL TRIALS

    May 1, 1999, 00:00

  • DP2- THE RELATIONSHIP BETWEEN PAYER TYPE AND HOSPITALIZATION RATES FOR ASTHMATICS SUBSEQUENT TO AN EMERGENCY ROOM VISIT

    May 1, 1999, 00:00

  • PNP15- RETROSPECTIVE DATABASE ANALYSIS- ADJUSTMENTS REQUIRED FOR ANTIPSYCHOTIC DOSING AND DURATION PATTERNS

    May 1, 1999, 00:00

  • PCVD4- AN ECONOMIC MODEL OF HYPERTENSION IN ONTARIO

    May 1, 1999, 00:00

  • WPE7- SCHIZOPHRENIA- HELPING THE DECISIONMAKER TO UNDERSTAND THE IMPACTS OF ATYPICAL ANTIPSYCHOTICS

    May 1, 1999, 00:00

  • TPCT3- COST-EFFECTIVENESS OF ANTIMALARIAL TREATMENT OF QUININE PLUS DOXYCYCLINE VERSUS ARTEMISININ PLUS DOXYCYCLINE IN PHUOC LONG HOSPITAL, VIETNAM

    May 1, 1999, 00:00

  • RD4- RELATIONSHIP AMONG DISEASE-SPECIFIC QUALITY OF LIFE AND CLINICAL CONSEQUENCES OF ASTHMA

    May 1, 1999, 00:00

  • PNP7- SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI) UTILIZATION PATTERNS IN PATIENTS WITH OR WITHOUT A DEPRESSION DIAGNOSIS

    May 1, 1999, 00:00

  • PUP4- IMPLEMENTATION OF PHARMACOECONOMIC ANALYSIS IN NORWAY. ARE THE USERS PREPARED?

    May 1, 1999, 00:00

  • PNP9- ANTIDEPRESSANT IMPACT ON SOCIAL FUNCTIONING- REBOXETINE VERSUS FLUOXETINE

    May 1, 1999, 00:00

  • PPR5- ESTIMATING HEALTHCARE COSTS IN THE ABSENCE OF FINANCIAL DATA- A CASE STUDY

    May 1, 1999, 00:00

  • PID2- INCREASED COST OF MANAGING AIDS IN THE LAST YEAR OF LIFE

    May 1, 1999, 00:00

  • PNP20- ANTIPSYCHOTIC UTILIZATION RATIOS- DIFFERENCES AMONG AGE, GENDER, AND PAYER COMBINATIONS

    May 1, 1999, 00:00

  • TPIL7- MEDICAL RESOURCE USE AND PAYER COSTS OF INPATIENT AND OUTPATIENT CARE RELATED TO EPILEPSY

    May 1, 1999, 00:00

  • PWM7- COST-EFFECTIVENESS OF ESTROGEN REPLACEMENT THERAPY (ERT) ON THE PREVENTION OF OSTEOPOROSIS- SHORT-TERM VERSUS LONG-TERM THERAPY

    May 1, 1999, 00:00

  • PCVD2- HYPERTENSION DISEASE MANAGEMENT- A RANDOMIZED, COMPARATIVE TRIAL

    May 1, 1999, 00:00

  • PCP9- THE ANALGESIC EFFICACY AND THERAPEUTIC ONSET OF ANALGESIA OF INTRAVENOUS AND INTRAMUSCULAR KETOROLAC (15 MG AND 30 MG), AND ORAL IBUPROFEN 800 MG IN THE EMERGENCY ROOM- A COMPARATIVE STUDY

    May 1, 1999, 00:00

  • PCD1- DIRECT AND INDIRECT COSTS OF CHEMOTHERAPY-INDUCED TOXICITY

    May 1, 1999, 00:00

  • RM3- THE USE OF ABCIXIMAB FOR PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY PATIENTS ENROLLED IN MANAGED CARE ORGANIZATIONS

    May 1, 1999, 00:00

  • PRD1- BARRIERS TO EFFECTIVE ASTHMA DISEASE MANAGEMENT- LIMITATIONS IN PHYSICIAN KNOWLEDGE OF TREATMENT GUIDELINES

    May 1, 1999, 00:00

  • PPO7- UTILIZATION OF AMBULATORY CARE SERVICES DUE TO ADVERSE EFFECTS OF MEDICATIONS IN THE UNITED STATES

    May 1, 1999, 00:00

  • PCVD3- COST-EFFECTIVENESS OF THROMBOLYTIC AGENTS IN THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION

    May 1, 1999, 00:00

  • WPE5- ANALYSES OF OUTCOME DOMAINS IN SCHIZOPHRENIA- METHODOLOGIES AND RESULTS FROM THE SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (SCAP)

    May 1, 1999, 00:00

  • WPE8- DESIGNING NATURALISTIC OUTCOMES TRIALS THAT ARE APPLICABLE TO THE 'REAL WORLD' OF CLINICAL PRACTICE

    May 1, 1999, 00:00

  • PCP7- COSTS AND OUTCOMES OF REGIONAL VERSUS GENERAL VERSUS COMBINATION ANESTHESIA AND ANALGESIA TECHNIQUES IN GREEK PATIENTS UNDERGOING HIP ARTHROPLASTY

    May 1, 1999, 00:00

  • TPQL1- DEVELOPMENT AND PSYCHOMETRIC VALIDATION OF A QUALITY OF LIFE QUESTIONNAIRE IN URINARY INCONTINENCE (CONTILIFE)

    May 1, 1999, 00:00

  • PKU7- COST UTILITY ANALYSIS OF LIVER AND KIDNEY TRANSPLANTATION IN GERMANY

    May 1, 1999, 00:00

  • PAD6- ASSESSMENT OF THE ECONOMIC AND HUMANISTIC OUTCOMES OF THE WEST VIRGINIA MEDICAIDS PRIOR AUTHORIZATION POLICY FOR NSAIDS

    May 1, 1999, 00:00

  • PRD7- THE USE OF GENERALIZED ESTIMATING EQUATIONS IN LONGITUDINAL STUDIES OF RESOURCE UTILIZATION- THE CASE OF ASTHMA

    May 1, 1999, 00:00

  • PNP11- DIABETES MELLITUS AND OTHER CARDIOVASCULAR RISK FACTORS IN PATIENTS RECEIVING ANTIDEPRESSANT DRUGS

    May 1, 1999, 00:00

  • TPIC5- TELEPHONY AS A COST-EFFICIENT METHOD FOR ASSESSING HEALTHCARE UTILIZATION (HCU) AND PRODUCTIVITY LOSS (PL) IN AN EMPLOYED POPULATION

    May 1, 1999, 00:00

  • WMQ3- EVALUATING HIV DISEASE HEALTH OUTCOMES IN DIFFERENT TREATMENT SETTINGS- HOW TO SELECT THE MOST APPROPRIATE HRQL INSTRUMENT

    May 1, 1999, 00:00

  • TPQL7- THE EFFECT OF ORDER OF ADMINISTRATION OF GENERIC AND DISEASE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRES

    May 1, 1999, 00:00

  • POR7- DEVELOPING A QUALITY ASSESSMENT SCORING SYSTEM FOR ECONOMIC EVALUATIONS

    May 1, 1999, 00:00

  • WMS3- SOFTWARE FOR COST-EFFECTIVENESS STATISTICAL INFERENCE

    May 1, 1999, 00:00

  • PCD3- COSTS AND OUTCOMES OF HOME VERSUS HOSPITAL-BASED TREATMENT OF FEBRILE NEUTROPENIA IN PEDIATRIC ONCOLOGY PATIENTS

    May 1, 1999, 00:00

  • PG17- RATE OF GI DISTRESS AMONG PATIENTS TREATED WITH CELECOXIB, PLACEBO, OR NSAIDs USING THREE DIFFERENT STATISTICAL METHODS

    May 1, 1999, 00:00

  • DM3- IMPLEMENTATION OF NATIONAL CHOLESTEROL GUIDELINES- A MULTIDISCIPLINARY APPROACH TO HYPERLIPIDEMIA DISEASE MANAGEMENT

    May 1, 1999, 00:00

  • PCVD12- EFFECTS OF AN EDUCATIONAL CAMPAIGN ON MEDICATION USE FOR CORONARY ARTERY DISEASE (CAD)

    May 1, 1999, 00:00

  • PPR1- PRE-TEST OF A MARKOV MODEL TO ESTIMATE THE COST OF ILLNESS IN AMBULATORY PATIENTS- A PRELIMINARY ESTIMATE USING PHYSICIAN SURVEY DATA

    May 1, 1999, 00:00

  • WDM1- CURRENT COMPUTER SOFTWARE AND HARDWARE OPTIONS IN PHARMACOECONOMICS- SPREADSHEETS, DECISION ANALYSIS, INTERNET, AND EDUCATIONAL TOOLS

    May 1, 1999, 00:00

  • WMS2- PITFALLS WHEN USING REGRESSION EQUATIONS TO ESTIMATE TREATMENT IMPACT IN ACTUAL PRACTICE

    May 1, 1999, 00:00

  • WPE10- GUIDELINES FOR THE ECONOMIC EVALUATION OF PHARMACEUTICALS- CURRENT USE AND EMERGING TRENDS

    May 1, 1999, 00:00

  • TPDM5- COST-BENEFIT ANALYSIS OF AN INTRAUTERINE LEVONORGESTREL-RELEASING DEVICE MIRENA VERSUS HYSTERECTOMY FOR WOMEN WITH MENORRHAGIA

    May 1, 1999, 00:00

  • PCD5- RELIABILITY AND VALIDITY OF THE BREAST EVALUATION QUESTIONNAIRE (BEQ)- AN OUTCOME MEASURE FOR BREAST IMPLANT STUDIES

    May 1, 1999, 00:00

  • PID9- EVALUATION OF THE OUTCOMES OF PATIENTS ON HEMODIALYSIS RECEIVING AMPHOTERICIN B LIPID COMPLEX (ABLC)

    May 1, 1999, 00:00

  • WMM5- USING EPIDEMIOLOGIC DATABASES TO EXTRAPOLATE LONG-TERM OUTCOMES FROM SURROGATE MARKER DATA

    May 1, 1999, 00:00

  • PKU5- ACUTE REJECTION EPISODES ARE ASSOCIATED WITH HIGHER UTILIZATION OF RESOURCES AFTER KIDNEY TRANSPLANTATION

    May 1, 1999, 00:00

  • TPQL6- THE PERFORMANCE OF A GENERIC MEASURE (EQ-5D) IN ASSESSING MENTAL HEALTH OUTCOMES

    May 1, 1999, 00:00

  • WMQ1- THE SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM HEALTH QUESTIONNAIRE (SCAP-HQ)- A BRIEF INSTRUMENT TO ASSESS OUTCOMES OF CARE IN SCHIZOPHRENIA

    May 1, 1999, 00:00

  • PID19- COST-EFFECTIVENESS OF ONCE-DAILY CLARITHROMYCIN COMPARED TO AMOXYCILLIN/CLAVULANIC ACID IN THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS

    May 1, 1999, 00:00

  • POR5- EVALUATION OF THE ANALYTICAL HIERARCHY PROCESS (AHP) AS A TOOL IN FORMULARY DEVELOPMENT

    May 1, 1999, 00:00

  • PDD4- DEVELOPMENT OF HEALTH STATE DESCRIPTIONS OF DIABETIC PERIPHERAL NEUROPATHY FOR A NEW UTILITY INSTRUMENT

    May 1, 1999, 00:00

  • DP1- EFFECT OF DEMOGRAPHICS ON THE COST OF PHARMACEUTICALS IN A PRIVATE THIRD-PARTY PRESCRIPTION PROGRAM

    May 1, 1999, 00:00

  • PNP19- PSYCHOTROPIC PRESCRIBING FOR THE ELDERLY IN AMBULATORY CLINICS

    May 1, 1999, 00:00

  • PID13- LONG-TERM EFFICACY OF LOCAL GUIDELINES TO IMPROVE ANTITETANUS PROPHYLAXIS AND REDUCE COSTS IN AN EMERGENCY DEPARTMENT

    May 1, 1999, 00:00

  • PUP3- ANALYSIS OF THE ECONOMIC IMPACT OF AN INCREASE IN THE UTILIZATION OF GENERIC MEDICATIONS IN PORTUGAL

    May 1, 1999, 00:00

  • POR1- METHODOLOGY FOR DEVELOPING AN INDEX SCORE FOR BOTHERSOMENESS OF ADVERSE EVENTS

    May 1, 1999, 00:00

  • WMD2- THE WHAT, HOW, AND WHY OF THE DELPHI

    May 1, 1999, 00:00

  • PCP2- IMPACT OF PATIENT EDUCATION ON QUALITY OF LIFE IN HEADACHE TREATMENT

    May 1, 1999, 00:00

  • PPO11- NEW METHODS OF DATA COLLECTION IN THE COMMUNITY-BASED PHYSICIAN SETTING- OVERVIEW OF THE PROCESS AND PRESENTATION OF DESCRIPTIVE STATISTICS

    May 1, 1999, 00:00

  • PRD11- QUALITY OF LIFE ASSESSMENT IN ALLERGIC RHINITIS PATIENTS TREATED WITH LORATADINE

    May 1, 1999, 00:00

  • PNP5- PHARMACOECONOMIC ANALYSIS OF PATTERNS OF ANTIDEPRESSANT USE

    May 1, 1999, 00:00

  • ER1- THE APPLICATION OF MULTILEVEL MODELING AND CLUSTER ANALYSIS TO MULTINATIONAL ECONOMIC EVALUATION DATA

    May 1, 1999, 00:00

  • PCP4- LINGUISTIC VALIDATION OF THE PATIENT PERCEPTION OF MIGRAINE QUESTIONNAIRE (PPMQ) IN 16 LANGUAGES

    May 1, 1999, 00:00

  • PPR6- COST-EFFECTIVENESS ANALYSIS- A SIMULTANEOUS MARGINAL-EFFECT APPROACH

    May 1, 1999, 00:00

  • PWM6- IMPACT OF POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY ON RESOURCE UTILIZATION ASSOCIATED WITH ADVERSE EVENTS

    May 1, 1999, 00:00

  • PPR2- EVALUATION OF AN EDUCATIONAL INTERVENTION ON THE PERCEPTION OF COST-EFFECTIVE INFORMATION RELATIVE TO CLINICAL INFORMATION

    May 1, 1999, 00:00

  • PNP23- THE IMPACT OF ALCOHOL CONSUMPTION AND SMOKING ON SHORT-TERM HEALTHCARE COSTS IN A MANAGED CARE POPULATION

    May 1, 1999, 00:00

  • DISCLOSURE INFORMATION

    May 1, 1999, 00:00

  • PCVD16- THE ECONOMIC AND HEALTH BENEFITS OF CONVERSION TO NORMAL SINUS RHYTHM

    May 1, 1999, 00:00

  • TPDM2- COST-EFFECTIVENESS OF INCREASING WARFARIN USAGE FOR STROKE PROPHYLAXIS IN PATIENTS WITH ATRIAL FIBRILLATION

    May 1, 1999, 00:00

  • TPS6- COST-EFFECTIVENESS OF SCREENING AND TREATING DIABETIC RETINOPATHY IN TYPE I DIABETICS

    May 1, 1999, 00:00

  • TPCT2- COST-EFFECTIVENESS OF ABCIXIMAB IN PERCUTANEOUS CORONARY INTERVENTION PATIENTS- RESULTS FROM A META-ANALYSIS

    May 1, 1999, 00:00

  • DP3- USING SIMULATION MODELING TECHNIQUES TO FACILITATE THE MANAGEMENT OF THE WAITING LIST FOR LIVER TRANSPLANTATION

    May 1, 1999, 00:00

  • WDM3- APPLYING PRACTICAL APPLICATIONS OF PHARMACOECONOMICS AND OUTCOMES e DATA IN THE COMMUNITY HEALTHCARE FACILITY

    May 1, 1999, 00:00

  • TPRD7- ESTIMATING LIFE-EXPECTANCY IN POSTACUTE CORONARY SYNDROMES- THE IMPORTANCE OF TWO-COMPONENT SURVIVAL MODELS

    May 1, 1999, 00:00

  • PCP1- A THREE-PHASED DECISION ANALYTIC MODEL FOR THE ECONOMIC EVALUATION OF OPIOID THERAPY FOR CHRONIC PAIN

    May 1, 1999, 00:00

  • TPS2- COST ANALYSIS OF A DIAGNOSTIC SCREENING TO DIFFERENTIATE 30- TO 45-YEAR-OLD PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES MELLITUS

    May 1, 1999, 00:00

  • PDD2- PSYCHOMETRIC PROPERTIES OF THE PATIENT BENEFIT QUESTIONNAIRE (PBQ) IN A COHORT OF DIABETIC PERIPHERAL NEUROPATHY (DPN) PATIENTS

    May 1, 1999, 00:00

  • WPE3- HEALTH ECONOMISTS AND MANAGED CARE DECISION-MAKERS- BRIDGING THE GAP

    May 1, 1999, 00:00

  • TPCP2- PERCENTAGE OF ANTI-HYPERTENSIVE DRUGS 'FILLED AS INTENDED' COMPARING PHARMACY CLAIMS AND MEDICAL RECORDS DATA

    May 1, 1999, 00:00

  • PPO10- UNDERSTANDING THE PROCESS AND ROLE OF TECHNOLOGY ASSESSMENT IN LARGE HEALTH MAINTENANCE ORGANIZATIONS

    May 1, 1999, 00:00

  • PCD6- COMPARISON OF THE McMASTERS HEALTH UTILITIES INDEX-MARK III AND THE EUROQOL-5D IN A SURGICAL BREAST CANCER POPULATION

    May 1, 1999, 00:00

  • WTG5- EVALUATION OF FORMULARY DECISIONS- PROJECTED IMPACT OF A NEW DRUG ROLLOUT WITHIN THE MANAGED CARE ARENA

    May 1, 1999, 00:00

  • RM1- CONTROLLING FOR SIMULTANEITY BIAS IN OUTCOME STUDIES USING PANEL DATA

    May 1, 1999, 00:00

  • PPR7- A FORMAL AUDIT OF 228 PUBLISHED COST-UTILITY ANALYSES

    May 1, 1999, 00:00

  • WMD3- NEW METHODS OF DATA COLLECTION IN THE COMMUNITY-BASED PHYSICIAN SETTING- PROCESS AND TECHNOLOGY

    May 1, 1999, 00:00

  • CD1- HOSPITAL UTILIZATION AND COST AMONG PATIENTS WITH NONISCHEMIC HEART FAILURE IN THE FIRST PROSPECTIVE RANDOMIZED AMLODIPINE SURVIVAL EVALUATION STUDY (PRAISE)

    May 1, 1999, 00:00

  • PKU3- LINGUISTIC VALIDATION OF THE URINARY INCONTINENCE QUALITY OF LIFE QUESTIONNAIRE

    May 1, 1999, 00:00

  • TPCP6- THE ROLE OF ALTERNATIVE ANTIHYPERLIPIDEMIC DRUGS- PATIENT COMPLIANCE, HEALTHCARE UTILIZATION, AND HEALTHCARE COSTS

    May 1, 1999, 00:00

  • PCVD5- DELPHI PANEL SURVEY ON CURRENT HYPERTENSION TREATMENT PATTERNS

    May 1, 1999, 00:00

  • ID1- ESTIMATING THE COST-EFFECTIVENESS OF ANTIBIOTIC TREATMENT FOR ACUTE OTITIS MEDIA USING INSTRUMENTAL VARIABLE ESTIMATION TECHNIQUES

    May 1, 1999, 00:00

  • TPIC3- THE PRODUCTIVITY COSTS OF ALLERGIC RHINITIS

    May 1, 1999, 00:00

  • TPCT5- TREATMENT OF DIABETIC FOOT ULCERS WITH TOPICAL RECOMBINANT GROWTH FACTOR GEL ACHIEVES HIGHER HEALING RATES AND RESULTS IN LOWER PROJECTED COSTS OF CARE

    May 1, 1999, 00:00

  • TPCT4- COST-EFFECTIVENESS OF RABEPRAZOLE VERSUS RANITIDINE IN REFLUX ESOPHAGITIS

    May 1, 1999, 00:00

  • ID2- CHRONIC HEPATITIS C- COST-EFFECTIVENESS OF INTERFERON AND RIBAVIRIN

    May 1, 1999, 00:00

  • PID8- TREATMENT OF ONYCHOMYCOSIS OF THE NAIL IN A MEDICAID POPULATION

    May 1, 1999, 00:00

  • PCD9- UTILIZATION OF COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) TREATMENTS AMONG PROSTATE CANCER PATIENTS IN CaPSURE

    May 1, 1999, 00:00

  • PCVD13- ASSESSING LIPID-LOWERING INTERVENTIONS IN MANAGED CARE SETTINGS

    May 1, 1999, 00:00

  • PPO6- TIME-DEPENDENT SURVIVAL ANALYSIS OF A PHARMACISTS CONSULTATION INTERVENTION STUDY

    May 1, 1999, 00:00

  • WTG4- ECONOMIC EVALUATION OF PHARMACEUTICALS IN ISRAEL- CURRENT AND FUTURE NATIONAL POLICY

    May 1, 1999, 00:00

  • ND2- POTENTIAL SAVINGS IN THE COST OF TREATING ALZHEIMERS DISEASE- PATIENT TREATMENT WITH RIVASTIGMINE

    May 1, 1999, 00:00

  • PNP17- ECONOMIC BURDEN DUE TO COSTS OF PSYCHOTROPIC MEDICATIONS FOR THE MANAGEMENT OF PSYCHIATRIC DISORDERS IN INDIA

    May 1, 1999, 00:00

  • PRD8- A RETROSPECTIVE DATABASE STUDY OF PATIENT ADHERENCE WITH ASTHMA TREATMENT REGIMENS

    May 1, 1999, 00:00

  • DM4- COST-EFFECTIVENESS OF OCCUPATIONAL THERAPY ON HEALTHY ELDERLY PEOPLE

    May 1, 1999, 00:00

  • PNP13- DEVELOPMENT OF A COST CONSEQUENCES COMPUTER SIMULATION MODEL OF BIPOLAR DISORDER

    May 1, 1999, 00:00

  • RD1- TREATING ALLERGIC RHINITIS IN PATIENTS WITH COMORBID ASTHMA- THE RISK OF ASTHMA-RELATED HOSPITALIZATIONS AND EMERGENCY ROOM VISITS

    May 1, 1999, 00:00

  • TPDM6- DETERMINING COST DRIVERS IN A COSTEFFECTIVENESS ANALYSIS OF THREE TREATMENTS FOR OVERACTIVE BLADDER

    May 1, 1999, 00:00

  • PNP6- COST-BENEFIT ANALYSIS OF ORAL ANTIDEPRESSANTS IN THE MANAGEMENT OF MAJOR DEPRESSIVE DISORDER- A MANAGED CARE PERSPECTIVE

    May 1, 1999, 00:00

  • PNP8- DEPRESSION IN POOR, YOUNG WOMEN- FLUOXETINE VERSUS SERTRALINE

    May 1, 1999, 00:00

  • PAD5- RETROSPECTIVE EVALUATION OF CONCOMITANT GASTROINTESTINAL DRUG USE WITH NSAID THERAPY AMONG PATIENTS WITH ARTHRITIS

    May 1, 1999, 00:00

  • Recommendations for Evaluating the Validity of Quality of Life Claims for Labeling and Promotion

    Mar 1, 1999, 00:00

  • Panel 5- Application of Healthcare Intervention Economic Evaluations in Healthcare Decision-Making

    Mar 1, 1999, 00:00

  • Pharmacoeconomics- Identifying the Issues Overview and Advisory Panel Report Summary

    Mar 1, 1999, 00:00

  • Panel 4- Education and Skills Needed to Conduct, Interpret, and Use Economic Evaluations in Healthcare

    Mar 1, 1999, 00:00

  • Resources Used by Panelists

    Mar 1, 1999, 00:00

  • Panel 6- Addressing Questions of Bias, Credibility, and Quality in Health Economic Evaluations

    Mar 1, 1999, 00:00

  • Panel 3- Methodological Issues in Conducting Pharmacoeconomic Evaluations—Retrospective and Claims Database Studies

    Mar 1, 1999, 00:00

  • Panel 1- Methodological Issues in Pharmacoeconomic Evaluations—Clinical Studies

    Mar 1, 1999, 00:00

  • Panel 7- Communication and Reporting Health Economic Information

    Mar 1, 1999, 00:00

  • Panel 2- Methodological Issues in Conducting Pharmacoeconomic Evaluations—Modeling Studies

    Mar 1, 1999, 00:00

  • CAN1- COST-EFFECTIVENESS ANALYSIS OF HIGH-DOSE CHEMOTHERAPY WITH HEMATOPOIETIC RESCUE AS PRIMARY TREATMENT FOR METASTATIC BREAST CANCER

    Jan 1, 1999, 00:00

  • PMC1- MEDICATION COMPLIANCE AND EXPENDITURE IMPACT ASSOCIATED WITH PHARMACISTS COGNITIVE SERVICE INTERVENTIONS

    Jan 1, 1999, 00:00

  • MH4- ECONOMIC IMPACT OF AGITATED AND AGGRESSIVE BEHAVIORS OF ELDERLY INDIVIDUALS DWELLING IN THE COMMUNITY IN FRANCE- I. EPIDEMIOLOGY

    Jan 1, 1999, 00:00

  • CV1- PRELIMINARY QUALITY-OF-LIFE EVALUATION OF THE GERMAN SAT TRIAL- COMPARISON OF SF-36, EUROQOL, TIME TRADE-OFF METHOD, AND WILLINGNESS TO PAY METHOD

    Jan 1, 1999, 00:00

  • D2- PATIENT-HELD INSTRUMENTS FOR RECORDING AMBULATORY CARE RESOURCE USE- EXPERIENCE IN PATIENTS WITH DIABETIC FOOT ULCERS

    Jan 1, 1999, 00:00

  • PCA7- COST ESTIMATION OF SEVERE NEUTROPENIA IN BELGIUM

    Jan 1, 1999, 00:00

  • PCA10- THE RELATIONSHIP BETWEEN PROFILE-BASED QUALITY OF LIFE SCORES AND EUROQOL-5D SCORES IN BREAST CANCER SURGERY PATIENTS

    Jan 1, 1999, 00:00

  • PMH3- COST-EFFECTIVENESS OF FLUVOXAMINE IN THE TREATMENT OF RECURRENT DEPRESSION IN FRANCE

    Jan 1, 1999, 00:00

  • L2- EFFECTIVENESS OF ORAL CIPROFLOXACIN IN THE TREATMENT OF EXACERBATIONS OF CHRONIC AIRWAY DISEASES

    Jan 1, 1999, 00:00

  • CV2- COST-EFFECTIVENESS OF TREATING HIGH-RISK INDIVIDUALS, AGED 45-65, WITH STATINS IN GERMANY FOR PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART DISEASE

    Jan 1, 1999, 00:00

  • PCV1- COST-EFFECTIVENESS OF LIPID MODULATOR AGENTS

    Jan 1, 1999, 00:00

  • W5- A NATURAL HISTORY OF ALZHEIMERS DISEASE- PATH-DEPENDENT EVALUATION OF CLINICAL AND ECONOMIC OUTCOMES USING DECISION DATABASE METHODOLOGY

    Jan 1, 1999, 00:00

  • PCV9- COMPARISON OF THE EPIDEMIOLOGY AND COSTS ASSOCIATED WITH PRIMARY PREVENTION OF CORONARY HEART DISEASE IN FIVE EUROPEAN COUNTRIES

    Jan 1, 1999, 00:00

  • D1- SELF-MONITORING OF BLOOD GLUCOSE IN DIABETES- IS IT WORTH IT?

    Jan 1, 1999, 00:00

  • PMH2- CLINICAL AND ECONOMIC CHARACTERIZATION OF FAMILY MEDICINE PATIENTS RECEIVING ANTIDEPRESSANT DRUGS

    Jan 1, 1999, 00:00

  • PN2- RESULTS OF DISEASE MANAGEMENT IN HEADACHE TREATMENT

    Jan 1, 1999, 00:00

  • IM2- EPOETIN- REDUCES POSTOPERATIVE LENGTH OF STAY IN PATIENTS UNDERGOING KNEE REPLACEMENT

    Jan 1, 1999, 00:00

  • PMH4- THE BUDGET IMPACT PHARMACOTHERAPY SELECTION FOR MAJOR DEPRESSIVE DISORDER- A MULTINATIONAL STUDY

    Jan 1, 1999, 00:00

  • PCA8- COST-MINIMIZATION IN THE USE OF COLONY-STIMULATING FACTORS (CSFs) BASED ON CLINICAL PREDICTION MODELS (CPMs)

    Jan 1, 1999, 00:00

  • PCA5- QUALITY OF LIFE IN HODGKINS DISEASE- RESULTS FROM THE EORTC AND GHSG TRIALS

    Jan 1, 1999, 00:00

  • PMC3- SURVIVAL GAINS AND DEGREE OF THERAPEUTIC INNOVATION

    Jan 1, 1999, 00:00

  • PID2- COST-MINIMIZATION ANALYSIS OF CEFAMANDOLE AND TOBRAMYCIN VERSUS STANDARD THERAPY IN THE TREATMENT OF PATIENTS WITH LOCAL APPENDICULAR PERITONITIS

    Jan 1, 1999, 00:00

  • PMC6- ADVANCED SENSITIVITY ANALYSIS BY THE INTEGRATION OF POINT-SENSITIVITY AND RANGE-SENSITIVITY USING PROBABILITY DISTRIBUTIONS

    Jan 1, 1999, 00:00

  • Invited Speaker Biographical Summaries

    Jan 1, 1999, 00:00

  • Index

    Jan 1, 1999, 00:00

  • J2- REVIEW OF LEGISLATION RELATING TO PROMOTION OF MEDICINAL PRODUCTS IN THE EUROPEAN UNION-ARE HEALTH ECONOMICS DATA COVERED?

    Jan 1, 1999, 00:00

  • ND3- ECONOMIC EVALUATION OF ACAMPROSATE IN MAINTAINING ABSTINENCE IN ALCOHOL-DEPENDENT PATIENTS

    Jan 1, 1999, 00:00

  • ISPOR Inaugural European Conferen An Overview

    Jan 1, 1999, 00:00

  • PIM3- QUALITY OF LIFE SCORES AS PREDICTORS OF FUTURE HEALTHCARE RESOURCE USE IN PATIENTS WITH ARTHRITIS

    Jan 1, 1999, 00:00

  • PGIU1- WILLINGNESS TO PAY OF PATIENTS WITH PAINFUL-IRRITABLE BLADDER SYNDROME

    Jan 1, 1999, 00:00

  • PMC7- DIMINISHING THE COST OF HIGHLY PRESCRIBED DRUGS IN THE COMUNIDAD VALENCIANA (SPAIN)

    Jan 1, 1999, 00:00

  • PCIU3- THE EFFECTS OF ULCER-HEALING DRUG COPRESCIPTION ON NSAID-INDUCED GASTROINTESTINAL EVENTS- A RECORD LINKAGE COHORT STUDY

    Jan 1, 1999, 00:00

  • PCV7- CROSS-CULTURAL ADAPTATION OF THE SEATTLE ANGINA QUESTIONNAIRE (SAQ) IN I I COUNTRIES

    Jan 1, 1999, 00:00

  • MH1- ROAD TRAFFIC ACCIDENTS ARE ASSOCIATED WITH BENZODIAZEPINE USE

    Jan 1, 1999, 00:00

  • W11- DECISION ANALYSIS IN CANCER THERAPY, A NEW WAY FOR EVALUATION OUTCOMES WITH THE ANALYTIC HIERARCHY PROCESS (AHP)

    Jan 1, 1999, 00:00

  • MH2- NEW BENZODIAZEPINE USE IS ASSOCIATED WITH AN AGE-RELATED RISK OF HOSPITALIZATION WITH FRACTURE AND OTHER TRAUMA- A POPULATION-BASED STUDY

    Jan 1, 1999, 00:00

  • PIM1- COST-EFFECTIVENESS ANALYSIS OF A FIXED COMBINATION (DICLOFENAC 1 MISOPROSTOL) IN THE PREVENTION OF GASTROPATHY IN ARTHRITIS PATIENTS IN BELGIUM

    Jan 1, 1999, 00:00

  • PN6- IMPACT OF A COST-SHARING DRUG INSURANCE PLAN ON DRUG UTILIZATION AMONG INDIVIDUALS RECEIVING SOCIAL ASSISTANCE

    Jan 1, 1999, 00:00

  • Wl- THE DARTS DIABETES DATABASE- HOW CAN QUALITY OF LIFE MEASUREMENTS FOR OUTCOMES RESEARCH BE INCORPORATED?

    Jan 1, 1999, 00:00

  • PMC2- RUNNING COST OF TREATING A PATIENT IN A GENERAL MEDICAL WARD IN SULTAN QABOOS UNIVERSITY HOSPITAL IN OMAN

    Jan 1, 1999, 00:00

  • PCA9- QUALITY OF LIFE (QOL) OF PATIENTS WITH LOW-GRADE NON-HODGKINS LYMPHOMA (IG-NHL) TREATED WITH FLUDARABINE (F) OR CYCLOPHOSPHAMIDE-VINCRISTINE-PREDNISONE (CVP)

    Jan 1, 1999, 00:00

  • CV4- IMPROVED MYOCARDIAL PROTECTION DURING CORONARY BYPASS SURGERY SHORTENS HOSPITAL STAY AND SAVES COSTS

    Jan 1, 1999, 00:00

  • ID1- IS TRIMETHOPRIM RESISTANCE AN OUTCOME OF COMMUNITY ANTIBIOTIC PRESCRIBING?

    Jan 1, 1999, 00:00

  • PCV10- A HEALTH ECONOMIC EVALUATION OF HORMONE REPLACEMENT THERAPY IN BELGIUM

    Jan 1, 1999, 00:00

  • PMC4- LINKING HRQOLS TO LARGE NATIONAL DATA SETS- EUROQOL AND HUI INDICES

    Jan 1, 1999, 00:00

  • PCIU4- CROSS-CULTURAL ADAPTATION OF THE PATIENT ASSESSMENT OF CONSTIPATION-SYMPTOM QUESTIONNAIRE (PAC-SYM)

    Jan 1, 1999, 00:00

  • W8- THE DEVELOPMENT AND IMPLEMENTATION OF FORMULARY SUBMISSION GUIDELINES FOR MANAGED CARE IN THE UNITED STATES

    Jan 1, 1999, 00:00

  • W18- HEALTH STATUS AND QUALITY OF LIFE MEASURES IN INTERNATIONAL CLINICAL RESEARCH

    Jan 1, 1999, 00:00

  • W9- ECONOMIC EVALUATION OF REHABILITATION PROGRAMS- THE PERSPECTIVE OF SOCIAL OLD AGE INSURANCE FUNDS IN GERMANY

    Jan 1, 1999, 00:00

  • PCIU5- RATE OF GASTROPROTECTIVE AGENT USE, DIAGNOSTIC TESTS, AND HOSPITALIZATIONS AMONG ELDERLY PATIENTS WHO STARTED ARTHROTEC, A FIXED COMBINATION OF MISOPROSTOL AND DICLOFENAC

    Jan 1, 1999, 00:00

  • PMH8- EFFECT OF RISPERIDONE ON THE COST OF NURSING HOME CARE FOR RESIDENTS WITH BEHAVIORAL AND PSYCHOLOGICAL SIGNS AND SYMPTOMS

    Jan 1, 1999, 00:00

  • D4- MEASURING THE IMPACT OF DIABETIC FOOT ULCERS ON QUALITY OF LIFE FROM THE PATIENTS PERSPECTIVE

    Jan 1, 1999, 00:00

  • PIM2- COST OF ILLNESS IN EARLY RHEUMATOID ARTHRITIS STRATIFIED FOR SOCIAL STATUS

    Jan 1, 1999, 00:00

  • Wl2- DEVELOPING INTERACTIVE COMPUTER SOFTWARE FOR EVALUATING THE ECONOMIC AND CLINICAL OUTCOMES OF VARIOUS TREATMENT STRATEGIES

    Jan 1, 1999, 00:00

  • PN7- COST-EFFECTIVENESS OF PRAMIPEXOLE IN PARKINSONS DISEASE IN THREE COUNTRIES

    Jan 1, 1999, 00:00

  • PCV6- MEASURING DISEASE-SPECIFIC SYMPTOM IMPACT- DEVELOPMENT OF THE ATRIAL FIBRILLATION IMPACT SCALE (AFIS)

    Jan 1, 1999, 00:00

  • ND1- AN 11-YEAR, CONTROLLED STUDY OF HEALTHCARE RESOURCE USE AND MORTALITY FOR PATIENTS WITH PARKINSONS DISEASE

    Jan 1, 1999, 00:00

  • CV5- ECONOMIC ASSESSMENT OF A PROPHYLACTIC TREATMENT OF RECURRENCE OF ISCHEMIC ACCIDENTS BY LYSINE ACETYLSALICYLATE

    Jan 1, 1999, 00:00

  • PID1- COST-EFFECTIVENESS OF LEVOFLOXACIN VERSUS CLARITHROMYCIN IN PATIENTS EVALUABLE FOR CLINICAL EFFICACY IN THE TREATMENT OF ACUTE BACTERIAL SINUSITIS

    Jan 1, 1999, 00:00

  • PGIU2- EVALUATING CLINICAL OUTCOMES OF GERD TREATMENT OPTIONS USING DECISION ANALYSIS

    Jan 1, 1999, 00:00

  • ND4- CROSS-CULTURAL ADAPTATION OF THE MIGRAINE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE (MSQ) IN 14 LANGUAGES

    Jan 1, 1999, 00:00

  • Welccome

    Jan 1, 1999, 00:00

  • PCA1- PHARMACOECONOMIC EFFICIENCY OF THE USE OF PROTEASE INHIBITORS FOR HOSPITAL INPATIENTS WITH AIDS

    Jan 1, 1999, 00:00

  • IM1- ASSESSING THE VALUE OF EPOETIN-a VERSUS AUTOLOGOUS BLOOD DONATION IN ORTHOPEDIC SURGERY- A FEASIBILITY STUDY OF CONTINGENT VALUATION

    Jan 1, 1999, 00:00

  • PP1- CHARACTERISTICS OF CHRONIC AIRWAY DISEASE PATIENTS STARTED ON NEBULIZED IPRATROPIUM SOLUTION

    Jan 1, 1999, 00:00

  • MH5- ECONOMIC IMPACT OF AGITATED AND AGGRESSIVE BEHAVIORS OF ELDERLY INDIVIDUALS DWELLING IN THE COMMUNITY IN FRANCE- 2. COST ANALYSIS

    Jan 1, 1999, 00:00

  • W10- PRO AND CON- USE OF DATA FROM FOREIGN PHARMACOECONOMIC INVESTIGATIONS IN RUSSIA

    Jan 1, 1999, 00:00

  • MH6- COST-UTILITY ANALYSIS OF RISPERIDONE IN CHRONIC SCHIZOPHRENIA

    Jan 1, 1999, 00:00

  • PCV3- EFFICACY OF CARDIAC REHABILITATION THERAPY- A PROSPECTIVE MULTICENTER COHORT STUDY

    Jan 1, 1999, 00:00

  • PCA4- OUTCOME OF MONOCLONAL ANTIBODY 17-IA ADJUVANT THERAPY OF RESECTED COLON CANCER DUKES C IN GERMANY- A SUBGROUP ANALYSIS

    Jan 1, 1999, 00:00

  • ABSTRACT CONTRIBUTOR STATEMENTS OF FINANCIAL SUPPORT

    Jan 1, 1999, 00:00

  • PCA2- THE COST-EFFECTIVENESS OF ITRACONAZOLE SOLUTION IN THE TREATMENT OF ORAL CANDIDIASIS IN HIV/AIDS PATIENTS- AN INTERNATIONAL COMPARISON

    Jan 1, 1999, 00:00

  • CV6- OUTCOME OF ACUTE MYOCARDIAL INFARCTION PATIENTS WITH MAXIMAL INDIVIDUAL THERAPY (MITRA-STUDY)

    Jan 1, 1999, 00:00

  • PMC5- USING A SURROGATE SAMPLE TO DERIVE PATIENT PREFERENCES FOR A COST-UTILITY ANALYSES IN A RANDOMIZED CLINICAL TRIAL

    Jan 1, 1999, 00:00

  • MH3- ASSESSING THE SASKATCHEWAN DATABASE FOR OUTCOMES STUDIES OF DEPRESSION AND ITS TREATMENT

    Jan 1, 1999, 00:00

  • PN3- A FOUNDATION STUDY FOR COSTEFFECTIVENESS ANALYSIS- THE DEFINITION OF ECONOMIC PARAMETERS AND CLINICAL ENDPOINTS IN PARKINSONS DISEASE

    Jan 1, 1999, 00:00

  • PP4- ECONOMIC IMPACT OF SMOKING IN GERMANY

    Jan 1, 1999, 00:00

  • PMC8- META-ANALYSIS OF ECONOMIC EVALUATIONS- A METHODOLOGICAL APPROACH AND CASE STUDY

    Jan 1, 1999, 00:00

  • CAN3- PRACTICE PATTERNS OF CHEMOTHERAPY USAGE AND ASSOCIATED NEUTROPENIA AND FEBRILE NEUTROPENIA (FN) IN EUROPE

    Jan 1, 1999, 00:00

  • PD1- COMPLIANCE WITH AMERICAN DIABETIC ASSOCIATION (ADA) RECOMMENDATIONS IN A TYPE 2 DIABETIC POPULATION IN AN ACADEMIC FAMILY MEDICINE CENTER

    Jan 1, 1999, 00:00

  • W4- MONTE CARLO SIMULATION IN HEALTHCARE MODELS

    Jan 1, 1999, 00:00

  • PCA6- COST-EFFECTIVENESS OF GEMCITABINE AS FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED PANCREATIC CANCER

    Jan 1, 1999, 00:00

  • W20- STANDARD PROCEDURES FOR ECONOMIC EVALUATION- USING A COMPUTER PROGRAM FOR REPORTING ECONOMIC EVALUATIONS RESULTS (REER)

    Jan 1, 1999, 00:00

  • D3- ANTITHYROID DRUGS OR RADIOIODINE AS FIRST-LINE THERAPY OF GRAVES HYPERTHYROIDISM IN A COUNTRY WITH STRICT REGULATIONS FOR RADIATION PROTECTION?

    Jan 1, 1999, 00:00

  • PMH5- COST OF ALZHEIMERS DISEASE CARE IN THE UNITED KINGDOM

    Jan 1, 1999, 00:00

  • GI2- DIGEST INTERNATIONAL SURVEY- IMPACT OF UPPER GASTROINTESTINAL SYMPTOMS ON RESOURCE UTILIZATION AND QUALITY OF LIFE

    Jan 1, 1999, 00:00

  • J1- IDENTIFYING INITIAL DIAGNOSIS IN DATABASE RESEARCH

    Jan 1, 1999, 00:00

  • L1- COMPLIANCE WITH INHALED CORTICOSTEROIDS AND HOSPITALIZATION FOR ASTHMA

    Jan 1, 1999, 00:00

  • W3- ESTIMATING POPULATION BUDGET AND HEALTH IMPACTS OF NEW TREATMENTS

    Jan 1, 1999, 00:00

  • PMH7- CROSS-CULTURAL ADAPTATION OF THE INTERNATIONAL INDEX OF ERECTILE FUNCTION (IIEF) IN 31 COUNTRIES

    Jan 1, 1999, 00:00

  • PCV2- ADAPTING ECONOMIC ANALYSES FROM ONE COUNTRY TO ANOTHER- DO THE WOSCOPS UK FINDINGS HOLD IN BELGIUM?

    Jan 1, 1999, 00:00

  • L4- CROSS-CULTURAL ADAPTATION OF THE PEDIATRIC ASTHMA CAREGIVER QUALITY OF LIFE QUESTIONNAIRE (PACQLQ) IN 19 COUNTRIES

    Jan 1, 1999, 00:00

  • W19- THE BOOTSTRAP STATISTICAL METHOD FOR THE PHARMACOECONOMIC COST ANALYSIS OF SKEWED DATA

    Jan 1, 1999, 00:00

  • GI3- THE EFFECT OF AN OPEN ACCESS ENDOSCOPY SERVICE ON PRESCRIBING COSTS OF ULCER-HEALING DRUGS

    Jan 1, 1999, 00:00

  • PCV4- THE ECONOMIC IMPACT OF HYPERTENSION STUDY FROM THE PISTOIA PROJECT

    Jan 1, 1999, 00:00

  • PN4- QUALITY OF LIFE AND FUNCTIONAL STATUS MEASURES IN ADVANCED PARKINSONS PATIENTS TREATED WITH PRAMIPEXOLE, BROMOCRIPTINE, OR PLACEBO

    Jan 1, 1999, 00:00

  • W15- SELF-REPORTED RESOURCE UTILIZATION DATA IN PHARMACOECONOMIC TRIALS- THEIR USE AND IMPACT ON STUDY VALIDITY

    Jan 1, 1999, 00:00

  • W6- THE APPROPRIATENESS OF COMMON MEDICAL DATA SOURCES- RANDOMIZED TRIALS, META-ANALYSES, EPIDEMIOLOGICAL AND OBSERVATIONAL STUDIES FOR PHARMACOECONOMIC ANALYSES

    Jan 1, 1999, 00:00

  • PCV5- POTENTIAL COST SAVINGS OF THE 4 FRENCH INFINITI CATHETER IN DIAGNOSTIC CORONARY ANGIOGRAPHY

    Jan 1, 1999, 00:00

  • WI7- STANDARDIZATION IN THE PUBLIC HEALTH SYSTEM OF RUSSIA- THE FIRST EXPERIENCE

    Jan 1, 1999, 00:00

  • W2- ESTIMATING DRUG EFFECTS- FROM CLINICAL TRIAL RESULTS TO ACTUAL PRACTICE

    Jan 1, 1999, 00:00

  • GI1- COST-UTILITY ANALYSIS OF LAPAROSCOPIC VERSUS OPEN SURGERY FOR COLONIC DISEASE

    Jan 1, 1999, 00:00

  • W7- HANDLING SURVIVAL DATA IN COST-EFFECTIVENESS ANALYSIS

    Jan 1, 1999, 00:00

  • PP3- INCREMENTAL COST OF DISEASE IN NOSOCOMIAL PNEUMONIA FROM A HOSPITALS PERSPECTIVE- A FEASIBILITY STUDY

    Jan 1, 1999, 00:00

  • L3- QUALITY OF LIFE OF ASTHMA PATIENTS RELATIVE TO ASTHMA SEVERITY

    Jan 1, 1999, 00:00

  • W13- THE USE OF PROXIES TO COLLECT HEALTHCARE RESOURCES AND QUALITY OF LIFE DATA

    Jan 1, 1999, 00:00

  • ID2- CIPROFLOXACIN IS MORE SUCCESSFUL AND COST-EFFECTIVE THAN TRIMETHOPRIM/SULFAMETHOXAZOLE IN THE ORAL AMBULATORY TREATMENT OF WOMEN WITH UNCOMPLICATED ACUTE PYELONEPHRITIS

    Jan 1, 1999, 00:00

  • CAN2- A NEW METHOD FOR EXPRESSING SURVIVAL AND LIFE EXPECTANCY IN CANCER PATIENTS

    Jan 1, 1999, 00:00

  • CV3- UTILIZATION OF ACE INHIBITORS IN CONGESTIVE HEART FAILURE AMONG THE ELDERLY IN QUEBEC

    Jan 1, 1999, 00:00

  • W14- DESIGNING AN INTERNATIONAL PIGGYBACK STUDY- PROVIDING THE FOUNDATION

    Jan 1, 1999, 00:00

  • PP2- THE EFFECT OF AGE ON COST-EFFECTIVENESS IN THE TREATMENT OF MODERATE ASTHMA

    Jan 1, 1999, 00:00

  • PMH1- ANNUAL DIRECT COSTS OF PSYCHOTROPIC MEDICATIONS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS IN INDIA

    Jan 1, 1999, 00:00

  • J3- HOW DO PATIENTS MAKE SATISFACTION JUDGMENTS? ANSWERS FROM STRUCTURAL EQUATION MODELING

    Jan 1, 1999, 00:00

  • Mission Statement and Objectives

    Jan 1, 1999, 00:00

  • PCA3- ECONOMIC CONSEQUENCES OF MONOCLONAL ANTIBODY 17-1A ADJUVANT THERAPY OF RESECTED DUKES C COLORECTAL CARCINOMA IN GERMANY

    Jan 1, 1999, 00:00

  • PN1- A UK PRIMARY CARE DATABASE (UKPCD)-UK MEDIPLUS AS A READILY AVAILABLE RESEARCH TOOL FOR DETERMINING THE INCIDENCE AND PREVALENCE OF MULTIPLE SCLEROSIS, ITS TREATMENT, PRESCRIPTION COSTS, AND REFERRALS IN UK PRACTICE

    Jan 1, 1999, 00:00

  • PMH6- DEVELOPMENT OF A NEW DISEASE-SPECIFIC QUALITY OF LIFE SCALE FOR USE IN SCHIZOPHRENIA

    Jan 1, 1999, 00:00

  • PN5- CROSS-CULTURAL ADAPTATION OF THE FUNCTIONAL ASSESSMENT OF MULTIPLE SCLEROSIS (FAMS) QUESTIONNAIRE IN NINE COUNTRIES

    Jan 1, 1999, 00:00

  • PCV8- IMPACT OF CLINICAL SENSITIVITY ANALYSIS IN AN EVALUATION OF PRIMARY PREVENTION OF CORONARY HEART DISEASE IN GERMANY

    Jan 1, 1999, 00:00

  • From Research into Practice- How Should Healthcare Organizations/Governments Decide about Lipid Therapy and Who Will Pay? Reactor Panel and Open Forum

    Nov 1, 1998, 00:00

  • Patient Education and Compliance- How to Make It Cost-Effective

    Nov 1, 1998, 00:00

  • What Is Happening in the Real World in Lipid Therapy and Is It Appropriate? The Need for a Paradigm Shift

    Nov 1, 1998, 00:00

  • A Managed Care Perspective

    Nov 1, 1998, 00:00

  • A Canadian Perspective

    Nov 1, 1998, 00:00

  • Willingness to Pay versus Willingness to Buy- What Defines Value in Healthcare?

    Nov 1, 1998, 00:00

  • Criteria for the Economic Evaluation of Lipid Studies in Health Systems

    Nov 1, 1998, 00:00

  • A Pharmacy Benefit Manager Perspective

    Nov 1, 1998, 00:00

  • Employer and Consumer Perspectives

    Nov 1, 1998, 00:00

  • Prevalence-Based Economic Evaluation

    Nov 1, 1998, 00:00

  • A US Military Perspective

    Nov 1, 1998, 00:00

  • Commentary on Langley and McKenney Papers

    Nov 1, 1998, 00:00

  • A UK Perspective

    Nov 1, 1998, 00:00

  • Economic Modeling and Sensitivity Analysis

    Sep 1, 1998, 00:00

  • Clinical Trials and External Validity

    Sep 1, 1998, 00:00

  • The Economics of Hypercholesterolemia and Lipid-Lowering Therapy- A Brief Historical Tour

    Sep 1, 1998, 00:00

  • Methodology Issues in Lipid Pharmacoeconomic Investigations. Reactor Panel and Open Forum

    Sep 1, 1998, 00:00

  • Compliance in the Real World

    Sep 1, 1998, 00:00

  • The ISPOR Lipid Conferen Pharmacoeconomics and Outcomes Modeling Issues

    Sep 1, 1998, 00:00

  • Lipid-Lowering Pharmacoeconomic Studies. Reactor Panel and Open Forum

    Sep 1, 1998, 00:00

  • A Direction for Value in Health

    Sep 1, 1998, 00:00

  • Use of Surrogate Measures in Cost-Effectiveness Analyses of Lipid-Lowering Therapies

    Sep 1, 1998, 00:00

  • Cardiovascular Disease and Lipoproteins- Available Evidence and Remaining Questions. Reactor Panel and Open Forum

    Jul 1, 1998, 00:00

  • Landmark Trials in Lipid Reduction

    Jul 1, 1998, 00:00

  • Introduction to the ISPOR Lipid Conference

    Jul 1, 1998, 00:00

  • Prevention of Heart Disease- Is LDL Reduction the Outcome of Choice? No, There Is More

    Jul 1, 1998, 00:00

  • Lipoproteins and Cardiovascular Disease- Biological Basis and Epidemiological Studies

    Jul 1, 1998, 00:00

  • Proceedings of the ISPOR Lipid Confren Pharmacoeconomics and Outcomes Research Issues of Lipid Therapy. The First General Session- Cardiovascular Disease and Lipoproteins- Available Evidence and Remaining Questions

    Jul 1, 1998, 00:00

  • Prevention of Heart Disease- Is LDL Reduction the Outcome of Choice? Absolutely Yes

    Jul 1, 1998, 00:00

  • Atherosclerosis, Acute Coronary Events, and Cholesterol-Lowering- A New Paradigm

    Jul 1, 1998, 00:00

  • Health and Economic Outcomes Modeling Practices- A Suggested Framework

    Jul 1, 1998, 00:00

  • ID4 Evaluation of the Cost-Effectiveness of Management Strategies in Cytomegalovirus Infection And Disease

    May 1, 1998, 00:00

  • PCV21 Cost Consequences of Acute Myocardial Infarction in Diabetic Patients-The First Year

    May 1, 1998, 00:00

  • PCV18 The Impact of Acute Renal Failure on Cost in Elderly Patients with Congestive Heart Failure

    May 1, 1998, 00:00

  • MHC3 Factors Predicting Potentially Inappropriate Psychotropic Prescribing for the Elderly

    May 1, 1998, 00:00

  • CC4 Cost-Benefit Analysis of Recombinant Erythropoietin in Premature Neonates

    May 1, 1998, 00:00

  • PHB5 The Responsiveness of Disease-Specific And Generic Health Measures to Changes in the Severity of Osteoarthritis

    May 1, 1998, 00:00

  • PMH14 Schizophrenia Management- Does Managed Care Influence Length of Stay in U.S. Hospitals?

    May 1, 1998, 00:00

  • MGB3 Postmarketing Outcomes Studies- Benefits And Risks

    May 1, 1998, 00:00

  • PGD3 Cost-Utility Relation of the Treatment of Diabetic Foot Lesion with Hyperbaric Oxygene Therapy Versus Standard Therapy

    May 1, 1998, 00:00

  • PGD1 The Effects of Community-Based Pharmaceutical Care Services on Asthma-Related Quality of Life

    May 1, 1998, 00:00

  • PIC1 Markov Chain Estimation of Life Expectancy of HIV-Infected Patients- Comparison of Two Treatment Alternatives

    May 1, 1998, 00:00

  • MGA1 Improving Clinical Outcomes by Integrating A Normalized, Standardized, Comparative Database into the Process of Clinical Quality Improvement

    May 1, 1998, 00:00

  • PMH11 Utlization Review of SSRI Therapy at A Mental Health Managed Care Organization

    May 1, 1998, 00:00

  • MHA4 SSRI Antidepressant Use Patterns and their Relation to Clinical Global Impressions Scores- A Naturalistic Study

    May 1, 1998, 00:00

  • CVA2 Cost-Effectiveness and Economic Efficiency- The Case of Statin Therapy in Secondary Prevention of Cornary Heart Disease

    May 1, 1998, 00:00

  • CC3 Modeling Side Effect Costs from Literature-Based Data- Steroid-Induced Side Effects in Renal Transplantation

    May 1, 1998, 00:00

  • MHA3 Comparison of Sumatriptan (IMITREX) and Over-the-Counter (OTC) Medication Use According to Migraine Severity

    May 1, 1998, 00:00

  • PHB3 Psychometric Evaluation of SF-12 in Osteoarthritis Clinical Trials

    May 1, 1998, 00:00

  • PGD15 Veterans Satisfaction with H2-Receptor Antagonist (H2RA) Drug Conversion

    May 1, 1998, 00:00

  • PMD6 Chronic Care Costs of New Medicare HMO Enrollees- Implications for Disease Management

    May 1, 1998, 00:00

  • CVA1 Economic Outcomes of Carotid Endrterectomy for Stroke

    May 1, 1998, 00:00

  • PIC7 Epoetin Alfa Administered to Academic Health Center Dialysis Patients- Comparison to HCFA Billing Records

    May 1, 1998, 00:00

  • PIC9 The Economic Impact of A Drug Information Service

    May 1, 1998, 00:00

  • MHA5 SSRI Antidepressant Use in Primary Care in the United Kingdom- A Multivariate Analysis

    May 1, 1998, 00:00

  • PMD10 The Development of A Patient Outcomes Software for Urologists- Capsure POS

    May 1, 1998, 00:00

  • DA2 The Role of Patient Registries in Disease Management and Outcomes Research

    May 1, 1998, 00:00

  • MHB3 Cost-Effectiveness Evaluation of New Antipsychotics

    May 1, 1998, 00:00

  • MM3 Development of Drug Use Performance Models as Measures of Patient Care

    May 1, 1998, 00:00

  • ID3 Prescribing Patterns for Treatment of Upper Respiratory Infections

    May 1, 1998, 00:00

  • PMD1 Information Technology in A Large Multi-Site Outcomes Study

    May 1, 1998, 00:00

  • UT3 The EuroQoL EQ-5D- An Outcome Measure for Use in Clinical And Economic Evaluation

    May 1, 1998, 00:00

  • CC5 Incremental Cost-Effectiveness Analysis Comparing 4-Layer Bandage System with And without Apligraf for the Outpatient Treatment of Venous Leg Ulcers

    May 1, 1998, 00:00

  • PMD12 The Paradox of League Tables

    May 1, 1998, 00:00

  • PGD11 Validity And Reliability of An American Translation of the St. Georges Respiratory Questionnaire

    May 1, 1998, 00:00

  • PGD6 A Managed Care Cost Analysis of the Treatment of Psoriasis

    May 1, 1998, 00:00

  • PMH3 Evaluation of Humanistic Outcomes for Patients on Selective Serotonin Reuptake Inhibitors

    May 1, 1998, 00:00

  • CM1 Estimating the Costs And Outcomes for Different Disease Management Strategies- A Case Study of Cyomegalovirus Infection And Disease

    May 1, 1998, 00:00

  • PIC8 Clinical And Economic Benefits of An Infectious Disease Approval Program

    May 1, 1998, 00:00

  • ID6 Cost-Effectiveness of Liposomal Daunorubicin Versus Liposomal Doxorubicin in Kaposi Sarcoma

    May 1, 1998, 00:00

  • CVA6 Confounding by Indication in Calcium Channel Blocker Treatment of Hypertension or Angina

    May 1, 1998, 00:00

  • MM4 Reconciling Decision Models with the Real World- The Cost-Effectiveness of Erythropoietin for Esrd-Related Anemia

    May 1, 1998, 00:00

  • CM5 Discounting Health Benefits in Pharmacoeconomic Analyses- Is It Justified?

    May 1, 1998, 00:00

  • PMD8 Prenatal Care And Birth Weight in the United States

    May 1, 1998, 00:00

  • PCV19 Evaluation of the Costs of Heart Failure in Belgium

    May 1, 1998, 00:00

  • PCV9 Study of Hypertensive Prescribing Practices

    May 1, 1998, 00:00

  • PCV20 Convenience Implications of A Single Bolus Thrombolytic

    May 1, 1998, 00:00

  • PMH1 The Economic Burden of Schizophrenia- Acute General Hospital Costs

    May 1, 1998, 00:00

  • CC6 Development of Asthma-Specific Outcomes Measures for Children

    May 1, 1998, 00:00

  • ID1 Randomised Prospective Study Comparing Cost-Effectiveness of Teicoplanin and Vancomycin As Second-Line Empiric Therapy for Infection in Neutropenic Patients

    May 1, 1998, 00:00

  • DA4 Construction of A Validated, Normalized, Granular Administrative Database And Its Use in Clinical Outcomes Improvement, Clinical Research, And Pharmacoeconomic Research

    May 1, 1998, 00:00

  • DM1 Interpreting And Using Costeffectiveness Results

    May 1, 1998, 00:00

  • PMH5 The Cost of Treating Schizophrenia in the California Medicaid (MEDI-CAL) Program

    May 1, 1998, 00:00

  • CVA3 Adherence to Hypertension Therapy- The Effect of Initial Drug Choice

    May 1, 1998, 00:00

  • PGD8 Comparison of Prevalence Rates of Low Back Disorders Obtained from Two Large National Claims Databases

    May 1, 1998, 00:00

  • PCV8 Readiness to Comply And Outcomes of Antihypertensive Therapy

    May 1, 1998, 00:00

  • MGA2 Disease Management in Hypertension- The Benefits of Meeting Guideline Goals for Blood Pressure

    May 1, 1998, 00:00

  • ID5 Socio-Economic Relevance of Inpatient Treatment of Skin And Soft Tissue Infections with Tazobactam/Piperacillin 0.5 g/2.0 g in Comparison with Amoxicillin/Clavlanic Acid, Ceftriaxone, And Cefotaxime

    May 1, 1998, 00:00

  • CM2 Clinical Intervention Assessment- Implementation of Default Values for Expediting the Calculation of Cost Savings And Cost Avoidances

    May 1, 1998, 00:00

  • PMH7 A General Model of the Effects of Alternative Sedative-Hypnotic Agents on the Costs of Motor Vehicle Accidents

    May 1, 1998, 00:00

  • DA8 Evaluating Health Outcomes And Pharmacoeconomic Literature

    May 1, 1998, 00:00

  • PMH12 Texas Medication Algorithm Project- Feasibility Study of Implementing Medication Algorithms in the Public Mental Health Sector

    May 1, 1998, 00:00

  • PHB1 Efficient Strategies for Osteoporosis Testing

    May 1, 1998, 00:00

  • PMD13 Application of Pharmacoeconomics And Outcomes Research in Formulary Decision-Making

    May 1, 1998, 00:00

  • PMH9 Month-to-Month Adherence with Antipsychotic Pharmacotherapy- A Comparison Between Atypical And Typical Antipsychotics

    May 1, 1998, 00:00

  • PHB8 Cost-Effectiveness of Hormone Therapy Versus Calcium Therapy- An Osteoporosis Markov Model

    May 1, 1998, 00:00

  • PIC4 Cost-Effectiveness of Piperacillin-Tazobactam Versus Ceftazidime in Patients with Febrile Neutropenia

    May 1, 1998, 00:00

  • PIC6 Using A Pneumonia-Specific Severity of Illness Model in Assessing Variation in Hospital Length of Stay for Community-Acquired Pneumonia Patients

    May 1, 1998, 00:00

  • CM6 The Use of Patient Self-Reports to Collect Health Care Resource Utilization Data

    May 1, 1998, 00:00

  • PIC11 A Health Economic Evaluation of Paclitaxel And Carboplatin Versus Vinorelbine And Cisplatin Combination Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer

    May 1, 1998, 00:00

  • MHC5 The EuroQol in Parkinsons Disease Research- Rated Current Health vs. Population-Derived Health State Preferences

    May 1, 1998, 00:00

  • MHA6 Evaluation of Antidepressant Utilization Patterns and Associated Depression Diagnoses among Patients in A National Managed Care Organization

    May 1, 1998, 00:00

  • PIC10 The Influence of Case Mix Bias On Costs of Hospitalisation for Lower Respiratory Tract Infection

    May 1, 1998, 00:00

  • MGB5 Adherence of Health Care Workers to Hepatitis B Vaccination (HBV) Policy is Influenced by Leadership

    May 1, 1998, 00:00

  • PGD5 Predicting Hospitalization of Patients with Diabetes Mellitus- An Application of the Bayesian Discriminant Analysis

    May 1, 1998, 00:00
  • «
  • 171
  • 172
  • 173
  • 174 (current)
  • 175